When it may be considered
A balanced clinical framework.
Compounded GLP-1 Medications: A Patient Decision Guide
A balanced explanation of what compounded means, what it does not mean, what individual review requires, and how to compare a compounded option with an FDA-approved medication.
Short answer
Compounded semaglutide or tirzepatide may be considered only after individual physician review and when applicable conditions are met. They are not FDA-approved, are not brand-identical, and results vary.
Important: Compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical. Eligibility and results vary.
The rule is patient-specific, not automatic
Section 503A addresses preparations for identified patients with valid prescriptions. When a difference from a commercial product is relied on, a dose, concentration, or ingredient change does not automatically create an exception. The prescriber must determine and document that the change produces a significant difference for that patient.
What a compounded prescription does not prove
- It does not establish FDA approval or brand equivalence.
- It does not guarantee a dose, result, or individual response.
- It does not guarantee that a particular certificate or lot record is available.
- Cost alone does not replace a documented individual clinical need.
Practical questions for the pharmacy
Ask for the pharmacy name, what will appear on the label, storage instructions, the beyond-use date, and what product or lot documentation is available. Answers depend on the pharmacy, formulation, and lot and should be confirmed before fulfillment.
Compare every realistic option
If an FDA-approved medication is accessible, clinically appropriate, and affordable, it deserves a direct comparison. Coverage, supply, dosing format, tolerance, preferences, total cost, and follow-up can change the decision. A compounded option is not automatically better or worse.
B12 and lipotropic services are separate
B12/MIC is not included in the $199 trial. It may be offered separately when clinically appropriate, with formulation and pricing confirmed during consultation. Adding B12 does not by itself make a preparation legally distinct.
Published pricing
- Physician review: $119; medication is billed separately.
- Compounded semaglutide: $499 for 90 days, equivalent to $166 per month.
- Compounded tirzepatide: $699 for 90 days, equivalent to $233 per month.
- One-month semaglutide trial: $199 with physician evaluation and, if the prescription is approved and a pharmacy can fulfill it for the patient's location, one month of medication. Packaging and shipping details are confirmed before fulfillment.
Pricing helps compare options; it is not a clinical or legal reason by itself. Eligibility, telehealth, and shipping depend on location and are confirmed during consultation.
Decision library
Compounded versus brand
Differences, limits, and alternatives.
503A versus 503B
An educational explanation.
Common questions
Pricing, eligibility, and follow-up.
Expanded decision guide
What compounded means in patient care
A compounded medication is a preparation made for a specific clinical situation under a pathway separate from FDA drug approval. Section 503A applies to qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. The clinic performs the medical evaluation but does not manufacture or dispense. If a compounded prescription is medically and legally appropriate, fulfillment depends on a dispensing pharmacy verified for the patient and location. Compounded semaglutide and tirzepatide are not FDA-approved, not brand-identical, and results vary.
A practical transparency record
- The clinician's name, license jurisdiction, and role in the decision.
- The dispensing pharmacy's legal name and state license record.
- The exact preparation, concentration, directions, storage instructions, and beyond-use date shown on the label.
- The patient-specific clinical rationale and any separate legal determination on which the prescription relies.
- Separate evaluation, medication, follow-up, renewal, and cancellation terms.
What responsible information does not promise
A license lookup does not prove the quality of every preparation. A document for one lot does not establish every quality attribute or predict a clinical outcome. Compounding status does not mean FDA approval, and an ingredient or dose description does not make a preparation interchangeable with a brand. Ask product-specific questions while keeping those limits visible.
When the approved route may be preferable
If an approved product is appropriate and accessible, its product-specific label and evidence can make it the more direct choice. If it is not a fit, the visit should document why and review alternatives. A general clinical reason to discuss compounding is distinct from the documented change that must produce a significant difference for an identified patient when the 503A exception is relied on. Cost and convenience do not replace either analysis.
Use this resource cluster in order
- Start with the status-first comparison.
- Review the 503A and 503B role guide.
- Verify the dispensing pharmacy in an official record.
- Read what quality documents can and cannot show.
- Confirm follow-up, urgent-contact, privacy, and total-cost terms.
Primary and official source trail
Read each source for the exact product, population, date, method, and limitation. A source supports only the claim it actually studied or the policy it actually states.
Common questions
What is a compounded medication?
It is a preparation for an identified patient under a pathway separate from FDA approval. Section 503A contains conditions about who may compound, the individual prescription, duplication of commercially available products, and other requirements. Medical evaluation and dispensing-pharmacy verification are separate roles.
Is it FDA-approved or brand-identical?
No. Compounded semaglutide and tirzepatide are not FDA-approved, are not brand-identical, and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary.
Does changing a dose or adding B12 automatically make compounding permitted?
No. A dose, concentration, or ingredient change is not enough by itself. When the significant-difference exception is relied on, the prescriber must determine and document that difference for the identified patient.
What should I ask about the pharmacy?
Ask for the pharmacy name, what will appear on the label, storage instructions, the beyond-use date, and what product or lot documentation is available. Documentation varies by pharmacy and product.
Does the $199 trial include B12?
No. The trial includes physician evaluation and, if the prescription is approved and a pharmacy can fulfill it for the patient's location, one month of compounded semaglutide. Packaging and shipping details are confirmed before fulfillment. B12/MIC is not included and may be offered separately only when clinically appropriate.
Regulatory source: FDA guidance on sections 503A and 503B. Consult an official source or legal counsel for current interpretation.
This page is educational and is not individual medical or legal advice. Rules, supply, and availability can change. Compounded medications are not FDA-approved or brand-identical. Results vary.
Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by those companies. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical. Results vary.